L Wang1, I Magen, P-Q Yuan, S R Subramaniam, F Richter, M-F Chesselet, Y Taché. 1. CURE: Digestive Diseases Research Center and Center for Neurobiology of Stress, Department of Medicine, Division of Digestive Diseases, David Geffen School of Medicine, University of California Los Angeles and Veteran Affairs Greater Los Angeles Healthcare System, Los Angeles, USA. lixinw@ucla.edu
Abstract
BACKGROUND: Prevalent non-motor symptoms of Parkinson's disease (PD) include gastrointestinal motor impairments and advanced stage PD displays pathological aggregates of α-synuclein in colonic enteric neurons. We previously showed that 12 months old mice overexpressing human wild type (WT) α-synuclein under the Thy1 promoter (Thy1-aSyn) displayed colonic motor dysfunction. We investigated functional gut alterations at earlier ages and histological correlates. METHODS: Defecation, gastric emptying (GE), and immunostaining for α-synuclein, peripheral choline acetyltransferase (pChAT), tyrosine hydroxylase (TH), neuronal nitric oxide synthase (nNOS), and vasoactive intestinal peptide (VIP) in distal colon myenteric plexuses were assessed in male Thy1-aSyn compared to littermate WT mice. KEY RESULTS: Thy1-aSyn mice aged 2.5-3 or 7-8 months old had 81% and 55% reduction in fecal pellet output, respectively, in the first 15 min of exposure to a novel environment. The reduction remained significant in the older group for 2-h, and subsequent refeeding resulted also in a 60% and 69% reduction of defecation in the first hour, respectively. Thy1-aSyn mice (8-10 months) displayed increased α-synuclein in the myenteric plexuses with abundant varicose terminals surrounding pChAT-immunoreactive (ir) neurons, and only a few, nNOS-ir neurons. There were no conspicuous changes in pChAT- and nNOS-ir neurons, or TH- and VIP-ir nerve fibers. Thy1-aSyn mice aged 4-18 months had normal GE. CONCLUSIONS & INFERENCES: The occurrence of over-production of pre-synaptic α-synuclein in colonic myenteric ganglia several months before the loss of striatal dopamine may provide an anatomical basis for interference with cholinergic neuronal activation, causing an early impairment in defecation to stimuli.
BACKGROUND: Prevalent non-motor symptoms of Parkinson's disease (PD) include gastrointestinal motor impairments and advanced stage PD displays pathological aggregates of α-synuclein in colonic enteric neurons. We previously showed that 12 months old mice overexpressing human wild type (WT) α-synuclein under the Thy1 promoter (Thy1-aSyn) displayed colonic motor dysfunction. We investigated functional gut alterations at earlier ages and histological correlates. METHODS: Defecation, gastric emptying (GE), and immunostaining for α-synuclein, peripheral choline acetyltransferase (pChAT), tyrosine hydroxylase (TH), neuronal nitric oxide synthase (nNOS), and vasoactive intestinal peptide (VIP) in distal colon myenteric plexuses were assessed in male Thy1-aSyn compared to littermate WT mice. KEY RESULTS:Thy1-aSynmice aged 2.5-3 or 7-8 months old had 81% and 55% reduction in fecal pellet output, respectively, in the first 15 min of exposure to a novel environment. The reduction remained significant in the older group for 2-h, and subsequent refeeding resulted also in a 60% and 69% reduction of defecation in the first hour, respectively. Thy1-aSynmice (8-10 months) displayed increased α-synuclein in the myenteric plexuses with abundant varicose terminals surrounding pChAT-immunoreactive (ir) neurons, and only a few, nNOS-ir neurons. There were no conspicuous changes in pChAT- and nNOS-ir neurons, or TH- and VIP-ir nerve fibers. Thy1-aSynmice aged 4-18 months had normal GE. CONCLUSIONS & INFERENCES: The occurrence of over-production of pre-synaptic α-synuclein in colonic myenteric ganglia several months before the loss of striatal dopamine may provide an anatomical basis for interference with cholinergic neuronal activation, causing an early impairment in defecation to stimuli.
Authors: G Gourcerol; L Wang; D W Adelson; M Larauche; Y Taché; M Million Journal: Am J Physiol Gastrointest Liver Physiol Date: 2009-03-19 Impact factor: 4.052
Authors: Edward Rockenstein; Margaret Mallory; Makoto Hashimoto; David Song; Clifford W Shults; Ingrid Lang; Eliezer Masliah Journal: J Neurosci Res Date: 2002-06-01 Impact factor: 4.164
Authors: D R Robertson; A G Renwick; B Macklin; S Jones; D G Waller; C F George; J S Fleming Journal: Eur J Clin Pharmacol Date: 1992 Impact factor: 2.953
Authors: Sudhakar R Subramaniam; Iddo Magen; Nicholas Bove; Chunni Zhu; Vincent Lemesre; Garima Dutta; Chris Jean Elias; Henry A Lester; Marie-Francoise Chesselet Journal: Neurobiol Dis Date: 2018-06-01 Impact factor: 5.996
Authors: Franziska Richter; Sudhakar R Subramaniam; Iddo Magen; Patrick Lee; Jane Hayes; Aida Attar; Chunni Zhu; Nicholas R Franich; Nicholas Bove; Krystal De La Rosa; Jacky Kwong; Frank-Gerrit Klärner; Thomas Schrader; Marie-Françoise Chesselet; Gal Bitan Journal: Neurotherapeutics Date: 2017-10 Impact factor: 7.620
Authors: Leo P Kelly; Paul M Carvey; Ali Keshavarzian; Kathleen M Shannon; Maliha Shaikh; Roy A E Bakay; Jeffrey H Kordower Journal: Mov Disord Date: 2013-11-04 Impact factor: 10.338